Cita APA

TO, C., JW, D., DC, D. V., JM, K., E, M., A, N., . . . BT, D. (2024). Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: Results from the 36-month TOPAZ study.

Citación estilo Chicago

TO, Crawford, et al. Long-term Efficacy, Safety, and Patient-reported Outcomes of Apitegromab in Patients With Spinal Muscular Atrophy: Results From the 36-month TOPAZ Study. 2024.

Cita MLA

TO, Crawford, et al. Long-term Efficacy, Safety, and Patient-reported Outcomes of Apitegromab in Patients With Spinal Muscular Atrophy: Results From the 36-month TOPAZ Study. 2024.